GSK Announces Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B, Meeting Primary Endpoints
GSK sits 60% above its 52-week low of $31.715.
Summary
GSK reported positive Phase III trial results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, demonstrating statistically significant functional cure rates and paving the way for global regulatory filings.
Key Events · Product Development and Regulatory · GSK
-
Positive Phase III Trial Results
Bepirovirsen met primary endpoints in the B-Well 1 and B-Well 2 pivotal Phase III trials for chronic hepatitis B (CHB).
-
Significant Functional Cure Rate Achieved
The drug demonstrated a statistically significant and clinically meaningful functional cure rate, a critical goal for CHB patients where current treatments offer low cure rates.
-
Potential First-in-Class Treatment
Bepirovirsen is positioned as a potential first-in-class, finite (six-month) therapeutic option for CHB, with an acceptable safety and tolerability profile.
-
Global Regulatory Filings Planned
GSK plans to submit for global regulatory approvals starting in Q1 2026 based on these positive results, aiming to address a major global health challenge.
Analysis · GSK · Life Sciences
GSK's investigational antisense oligonucleotide, bepirovirsen, achieved statistically significant and clinically meaningful functional cure rates in two pivotal Phase III trials for chronic hepatitis B (CHB). This represents a major advancement in treating CHB, a condition affecting over 250 million people globally with limited current functional cure options. The positive data supports planned global regulatory submissions from Q1 2026, positioning bepirovirsen as a potential first-in-class, finite treatment option and a backbone for future therapies. This significantly de-risks the drug's path to market and could be a substantial revenue driver for GSK.
At the time of this filing, GSK was trading at $50.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $103.4B. The 52-week trading range was $31.72 to $51.46. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.